

Aberdeen Standard Emerging Opportunities

Quarterly Investment Option Update

31 March 2020

Aim and Strategy

To provide investors with high capital growth over the medium to long term (3 to 5 years) by seeking exposure to emerging stock markets worldwide or companies with significant activities in emerging markets. The benchmark is the MSCI Emerging Markets Index. In seeking to achieve the objective, the investment manager may invest in securities which are not contained in the index used as the performance benchmark. This investment option primarily invests in a diversified portfolio of emerging market securities. The normal characteristics of this investment option are:

- low turnover the average holding period is around 4 years
- significant divergence from the benchmark
- low cash allocations, and
- a beta less than or equal to one.

On occasions (such as where the purchasing costs of the investment can be reduced), a portion of the investment may be directly invested in other investment vehicles managed by other Aberdeen Group companies. This investment option does not generally borrow to invest and is not hedged to the Australian dollar.

Investment Option Performance

To view the latest investment performances for each product please visit amp.com.au

Investment Option Overview

| Investment Category | Global Shares |
|--------------------------------|----------------|
| Suggested Investment timeframe | 3 - 5 years |
| Relative risk rating | 7 / Very High |
| Investment style | Specialist |
| Manager style | Single Manager |
| | |

| Asset Allocation | Benchmark (%) | Actual (%) |
|---------------------------|---------------|------------|
| Emerging Markets Equities | 100.0 | 98.4 |
| Cash | - | 1.6 |

| Sector Allocation | % |
|---|------|
| Energy | 3.0 |
| Materials | 6.1 |
| Industrials | 1.3 |
| Consumer Discretionary | 12.7 |
| Consumer Staples | 6.5 |
| Health Care | 1.3 |
| Financials | 31.3 |
| Information Technology | 17.9 |
| Communication Services | 12.8 |
| Utilities | 0.5 |
| Real Estate | 5.0 |
| Cash | 1.6 |
| | |
| Regional Allocation | % |
| Asia | 76.8 |
| Africa and Middle East | 2.3 |
| Emerging Europe | 7.2 |
| Latin America | 12.2 |
| UK | |
| Cash | 1.6 |
| | |
| Top Holdings | % |
| Tencent Holdings | 8.59 |
| TSMC | 7.40 |
| Samsung Electronics | 7.27 |
| Aberdeen Standard SICAV I - China A Equity Fund | 6.01 |
| Ping An Insurance | 4.34 |
| HDFC | 3.24 |
| AIA Group | 3.01 |
| China Resources Land | 2.85 |
| Naspers | 2.27 |
| Vale | 2.26 |

Investment Option Commentary

Over the period, emerging markets underperformed developed ones, albeit moderately and lagged the benchmark. Entering the sell-off, rapid capital flight had a more adverse impact on returns, particularly in falling markets that also suffered substantial currency depreciation. As such, the investment manager's overweight position to Latin America proved costly. The converse was true in Asia, where they were broadly underweight. This was due to the light exposure to both Korea and Taiwan, given their more stable currencies. Also, these North Asian markets had fared better, given their robust initial response to the outbreak.

In Latin America, their overweight to Brazil and Mexico were key detractors. In Brazil, the fledgling economic recovery was stopped in its tracks by the global slowdown, while in Mexico, the oil price war pressured the peso and damaged the country's status as an emerging market safe haven. At the stock level, poor accounting practices and management integrity hurt insurer IRB, which the investment manager sold subsequently. Meanwhile, Banco Bradesco detracted on concerns over further interest rate cuts and deteriorating asset quality, while state-owned oil producer Petrobras was hurt by the slump in oil prices.

The fund manager's exposure to China has a mixed impact on performance. Notably, Tencent was a top contributor as technology stocks proved resilient during the lockdown. Our indirect exposure to Tencent, via Prosus, also added to performance. Additionally, the ASI SICAV I China A Share Equity Fund helped performance, as several underlying holdings picked-up as the economy reignited. Other direct mainland holdings that did well included Wuxi Biologics which benefited as disruptions in Europe and in the US shifted outsourcing demand to the company. The stock also rose on expectations that it may secure clinical research projects related to covid-19 therapies. Conversely, the lack of exposure to mainland index heavyweights China Construction Bank, ICBC, along with e-commerce giants Alibaba and JD.com, hurt performance. The fund also benefited from its off-benchmark exposure to Hong Kong, particularly given the resilient currency, with holdings, such as AIA and Hong Kong Exchanges and Clearing doing well.

Elsewhere, in India, the ASI SICAV I Indian Equity Fund contributed as its high-quality underlying holdings proved defensive, while not holding some lower quality banks also helped. In contrast, Indonesia suffered a sharp currency decline and our exposure to banks and consumer stocks hurt. Astra International and BRI detracted as investors retreated amid lower interest rate and consumption expectations.

Market Commentary

Global emerging markets fell sharply in the first quarter of 2020, as markets sold off aggressively, pricing in the economic impact of the covid-19 pandemic. Governments across the world resorted to unprecedented measures to restrict movement to contain the spread of the infectious and deadly disease. These measures brought international travel to a standstill and severely hampered economic activity. Production and manufacturing indices across the world plummeted, while emerging market currencies slumped against the US dollar. Additionally, the oil price took a dive as Saudi Arabia and Russia embarked on a price war to gain market share at a time when global demand was softening.

Outlook

The investment manager remain cautious about the outlook for emerging-market equities in the near term. Given the recent market volatility and disruption to economic activity caused by the pandemic, global growth is likely to slowdown this year. Having said that, governments and policy makers' swift response in pumping liquidity into their economies is shoring up sentiment, as have pledges for more fiscal support to follow. Furthermore, they are encouraged by the effective pace of recovery after the lockdown in China where the outbreak began, and they are hopeful that global economic activity will bounce back as quickly in the second half of 2020. However, it is quite likely that earnings estimates for the year would need to be downgraded.

Given their focus on high-quality companies and sustainable businesses, they are less concerned that a single-year hit to earnings and cash flows would significantly impair their holdings' competitiveness or cause balance sheet concerns. In fact, recent results from some of their core defensive holdings have been robust and they've been reassured by their assessment of the impact from covid-19, as well as actions they're taking to mitigate losses.

Availability

| Product name | APIR |
|---|-----------|
| AMP Flexible Lifetime Super | AMP1531AU |
| AMP Flexible Super - Retirement account | AMP1591AU |
| AMP Flexible Super - Super account | AMP1579AU |
| CustomSuper | AMP1531AU |
| Flexible Lifetime - Allocated Pension | AMP1543AU |
| Flexible Lifetime Investment (Series 2) | AMP2031AU |
| SignatureSuper | AMP1555AU |
| SignatureSuper Allocated Pension | AMP1567AU |
| SignatureSuper Select | AMP1555AU |

Contact Details

Web: www.amp.com.au Email: askamp@amp.com.au Phone: 131 267



What you need to know

This publication has been prepared by AMP Life Limited ABN 84 079 300 379, AFSL No. 233671 (AMP Life). The information contained in this publication has been derived from sources believe to accurate and reliable as at the date of this document. Information provided in this investment option update are views of the underlying Investment Manager only and not necessarily the views of the AMP Group. No representation is given in relation to the accuracy or completeness of any statement contained in it. Whilst care has been taken in the preparation of this publication, to the extent permitted by law, no liability is accepted for any loss or damage as a result of reliance on this information. AMP Life is part of the AMP Group. In providing the general advice, AMP Life and AMP Group receives fees and charges and their employees and directors receive salaries, bonuses and other benefits.

The information in this document is of a general nature only and does not take into account your financial situation, objectives and needs. Before you make any investment decision based on the information contained in this document you should consider how it applies to your personal objectives, financial situation and needs, or speak to a financial planner.

The investment option referred to in this publication is available through products issued by AMP Superannuation Limited ABN 31 008 414 104, AFSL No. 233060 (ASL) and/or AMP Life. Before deciding to invest or make a decision about the investment options, you should read the current Product Disclosure Statement for the relevant product, available from ASL, AMP Life or your financial planner.

Any references to the "Fund", strategies, asset allocations or exposures are references to the underlying managed fund that the investment option either directly or indirectly invests in (underlying fund). The investment option's aim and strategy mirrors the objective and investment approach of the underlying fund. An investment in the investment option is not a direct investment in the underlying fund.

Neither AMP Life, ASL, any other company in the AMP Group nor underlying fund manager guarantees the repayment of capital or the performance of any product or particular rate of return referred to in this document. Past performance is not a reliable indicator of future performance.